Overall, further clinical trials in humans are necessary to demonstrate that dietary interventions can simultaneously influence the microbiome, intestinal permeability, inflammation, and neurocognitive symptoms, making them a compelling complementary strategy in the treatment of ME/CFS [10, 11, 13]
Hsieh, M., Liu, H., Wang, C., Huang, H., Lin, Y., Ko, Y., Wang, J., Chang, V., & Pang, J
When we run a peptide production batch, we produce all vial strengths (MG sizes) in the same run using the same raw material, lyophilization cycle, and fill/finish process
Some of the preclinical research has included preliminary results for: Inflammatory bowel disease: In mouse studies, KPV reduced inflammation and protected the gut barrier
pylori infection (65%) comparing with non-NAC group (20%) (Cammarota et al